IdeaSphere acquisition
This article was originally published in The Tan Sheet
Executive Summary
IdeaSphere looks to strengthen and expand its international healthcare business through its acquisition of Boehringer Ingelheim's Pharmaton multivitamin business, the brand management firm states Aug. 25 in a joint release announcing the deal. The purchase "complements not only our geographical strength in North America with attractive market positions but also provides access to other strategic markets for IdeaSphere in Europe, the Middle East, Latin America and Asia. Moreover, both of our companies emphasize science-based medicines," said IdeaSphere President and COO Mark Fox. Twinlab-owner IdeaSphere acquired Metabolife in November and received worldwide licensing rights to Weil Nutritional Supplements in January (1"The Tan Sheet," Nov. 14, 2005, In Brief and 2"The Tan Sheet, Jan. 23, 2006, In Brief). "Boehringer Ingelheim will continue to strengthen is Consumer Healthcare business by further building up the flagship and international core brands, e.g., Dulcolax, Buscopan and Antistax," Chairman of the Board of Managing Directors Alessandro Banchi noted in the release...
You may also be interested in...
Boehringer cancels divestiture
Boehringer Ingelheim has terminated a share purchase agreement for the sale of its Pharmaton nutritional supplement business to Grand Rapids, Mich.-based IdeaSphere, the German firm announces Feb. 16. Boehringer halted the divestment because IdeaSphere failed to fulfill "all their closing obligations in accordance with the contract," the company states. "We are disappointed that the parties were not able to reach agreement at this time to complete the Pharmaton transaction," says IdeaSphere President and COO Mark Fox in a same-day release. The companies entered the acquisition agreement in August 2006 (1"The Tan Sheet" Aug. 28, 2006, In Brief)...
Metabolife purchased
Ideasphere (ISI), owner of nutrition brands such as Twinlab and Nature's Herbs, has closed the transaction relating to its acquisition of supplement maker Metabolife, the firm announces Nov. 7. Key assets acquired include Metabolife's "core non-ephedra brands" such as Metabolife Ultra and Metabolife Complete and a lab facility which ISI will use to for product development. The firm expects the integration to be complete within 60 days. ISI initiated the purchase agreement when the Metabolife declared bankruptcy in July, but renegotiated the agreement after some "discrepancies in business practices" came to light in September (1"The Tan Sheet" Sept. 26, 2005, p. 10)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.